US5264423A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibitors for replication of retroviruses and for the expression of oncogene products
Assignee: United States Department of Health and Human Services
•
Filing: 1992-11-16
•
Granted: 1993-11-23
•
Expires: 2012-11-16
Abstract
Abstract Phosphorothioate oligodeoxyribonucleotide analogs can be used to prevent replication of foreign nucleic acids in the presence of normal living cells, as well as to inhibit the proliferation of neoplastic cells.
Inventors
- 👤 Jack S. Cohen
- 👤 Len Neckers
- 👤 Cy Stein
- 👤 She L. Loke
- 👤 Kazuo Shinozuka
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 15:52
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; C; C07; C07H; C07H21/00; C07H21/04; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1131; C12N15/1132; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/315; C12N2310/33; C12N2310/335; C12N2310/35; C12N2310/352; C12N2310/3521
Claims Analysis
Total Claims: 54
Claim 1
Independent Claim
88 words
A compound capable of inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host, the compound having the formula: ##STR3## wherein: n is in the range of from 2 to 30, inclusive; X is selected from the group consisting of methyl, ethoxy, S and O such that at least one X is S; and B is selected from the group consisting of adenine, cytosine, guanine, and thymine, such that the compound has a complementary base sequence with a portion of the foreign nucleic acid.
Claim 2
Dependent Claim
88 words
A compound capable of inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host, the compound having the formula: ##STR3## wherein: n is in the range of from 2 to 30, inclusive; X is selected from the group consisting of methyl, ethoxy, S and O such that at least one X is S; and B is selected from the group consisting of adenine, cytosine, guanine, and thymine, such that the compound has a complementary base sequence with a portion of the foreign nucleic acid.
Claim 3
Dependent Claim
16 words
The compound of claim 1 wherein n is in the range of 14 to 30, inclusive.
Claim 4
Dependent Claim
15 words
The compound of claim 2 wherein said foreign nucleic acid is a viral nucleic acid.
Claim 5
Dependent Claim
18 words
The compound of claim 3 wherein said viral nucleic acid is a nucleic acid of human immunodeficiency virus.
Claim 6
Dependent Claim
19 words
The compound of claim 4 wherein said nucleic acid of human immunodeficiency virus is a gag gene nucleic acid.
Claim 7
Dependent Claim
19 words
The compound of claim 4 wherein said nucleic acid of human immunodeficiency virus is a tat-III gene nucleic acid.
Claim 8
Dependent Claim
19 words
The compound of claim 4 wherein said nucleic acid of human immunodeficiency virus is a art/trs gene nucleic acid.
Claim 9
Dependent Claim
20 words
The compound of claim 4 wherein said nucleic acid of human immunodeficiency virus is a reverse transcriptase gene nucleic acid.
Claim 10
Dependent Claim
15 words
The compound of claim 2 wherein said foreign nucleic acid is an oncogene nucleic acid.
Claim 11
Dependent Claim
15 words
The compound of claim 9 wherein said oncogene nucleic acid is a c-myc nucleic acid.
Claim 12
Dependent Claim
14 words
The compound of claim 2 wherein greater than 95 percent of X are S.
Claim 13
Dependent Claim
99 words
A composition for inhibiting the replication of cytopathic effect of a foreign nucleic acid in a host, the composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound of the formula: ##STR4## wherein: n is in the range of from 2 to 30, inclusive; X is selected from the group consisting of methyl, ethoxy, S and O such that at least one X is S; and B is selected from the group consisting of adenine, cytosine, guanine, and thymine, such that the compound has a complementary base sequence with a portion of the foreign nucleic acid.
Claim 14
Dependent Claim
99 words
A composition for inhibiting the replication of cytopathic effect of a foreign nucleic acid in a host, the composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound of the formula: ##STR4## wherein: n is in the range of from 2 to 30, inclusive; X is selected from the group consisting of methyl, ethoxy, S and O such that at least one X is S; and B is selected from the group consisting of adenine, cytosine, guanine, and thymine, such that the compound has a complementary base sequence with a portion of the foreign nucleic acid.
Claim 15
Dependent Claim
16 words
The composition of claim 12 wherein n is in the range of 14 to 30, inclusive.
Claim 16
Dependent Claim
15 words
The composition of claim 13 wherein said foreign nucleic acid is a viral nucleic acid.
Claim 17
Dependent Claim
18 words
The composition of claim 14 wherein said viral nucleic acid is a nucleic acid of human immunodeficiency virus.
Claim 18
Dependent Claim
19 words
The composition of claim 15 wherein said nucleic acid of human immunodeficiency virus is a gag gene nucleic acid.
Claim 19
Dependent Claim
19 words
The composition of claim 15 wherein said nucleic acid of human immunodeficiency virus is a tat-III gene nucleic acid.
Claim 20
Dependent Claim
19 words
The composition of claim 15 wherein said nucleic acid of human immunodeficiency virus is a art/trs gene nucleic acid.
Claim 21
Dependent Claim
20 words
The composition of claim 15 wherein said nucleic acid of human immunodeficiency virus is a reverse transcriptase gene nucleic acid.
Claim 22
Dependent Claim
15 words
The composition of claim 13 wherein said foreign nucleic acid is an oncogene nucleic acid.
Claim 23
Dependent Claim
15 words
The composition of claim 19 wherein said oncogene nucleic acid is a c-myc nucleic acid.
Claim 24
Dependent Claim
14 words
The composition of claim 13 wherein greater than 95 percent of X are S.
Claim 25
Independent Claim
99 words
A method for inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host comprising the step of administering to the host an effective amount of a compound of the formula: ##STR5## wherein: n is in the range of from 2 to 30, inclusive; X is selected from the group consisting of methyl, ethoxy, S and O such that at least one X is S; and B is selected from the group consisting of adenine, cytosine, guanine, and thymine, such that the compound has a complementary base sequence with a portion of the foreign nucleic acid.
Claim 26
Independent Claim
99 words
A method for inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host comprising the step of administering to the host an effective amount of a compound of the formula: ##STR5## wherein: n is in the range of from 2 to 30, inclusive; X is selected from the group consisting of methyl, ethoxy, S and O such that at least one X is S; and B is selected from the group consisting of adenine, cytosine, guanine, and thymine, such that the compound has a complementary base sequence with a portion of the foreign nucleic acid.
Claim 27
Dependent Claim
16 words
The method of claim 23 wherein n is in the range of 14 to 30, inclusive.
Claim 28
Dependent Claim
15 words
The method of claim 24 wherein said foreign nucleic acid is a viral nucleic acid.
Claim 29
Dependent Claim
18 words
The method of claim 25 wherein said viral nucleic acid is a nucleic acid of human immunodeficiency virus.
Claim 30
Dependent Claim
19 words
The method of claim 26 wherein said nucleic acid of human immunodeficiency virus is a reverse transcriptase nucleic acid.
Claim 31
Dependent Claim
26 words
The method of claim 27 wherein said step of administering includes administering said compound so that a blood concentration of 0.1 to 100 micromoles/cl is achieved.
Claim 32
Dependent Claim
15 words
The method of claim 27 wherein at least 95 percent of said X are S.
Claim 33
Dependent Claim
19 words
The method of claim 26 wherein said nucleic acid of human immunodeficiency virus is a gag gene nucleic acid.
Claim 34
Dependent Claim
26 words
The method of claim 30 wherein said step of administering includes administering said compound so that a blood concentration of 0.1 to 100 micromoles/cl is achieved.
Claim 35
Dependent Claim
15 words
The method of claim 30 wherein at least 95 percent of said X are S.
Claim 36
Dependent Claim
19 words
The method of claim 27 wherein said nucleic acid of human immunodeficiency virus is a tat-III gene nucleic acid.
Claim 37
Dependent Claim
26 words
The method of claim 33 wherein said step of administering includes administering said compound so that a blood concentration of 0.1 to 100 micromoles/cl is achieved.
Claim 38
Dependent Claim
15 words
The method of claim 33 wherein at least 95 percent of said X are S.
Claim 39
Dependent Claim
19 words
The method of claim 26 wherein said nucleic acid of human immunodeficiency virus is an art/trs gene nucleic acid.
Claim 40
Dependent Claim
26 words
The method of claim 36 wherein said step of administering includes administering said compound so that a blood concentration of 0.1 to 100 micromoles/cl is achieved.
Claim 41
Dependent Claim
15 words
The method of claim 36 wherein at least 95 percent of said X are S.
Claim 42
Dependent Claim
15 words
The method of claim 24 wherein a foreign nucleic acid is an oncogene nucleic acid.
Claim 43
Dependent Claim
15 words
The method of claim 39 wherein said oncogene nucleic acid is a c-myc nucleic acid.
Claim 44
Dependent Claim
26 words
The method of claim 40 wherein said step of administering includes administering said compound so that a blood concentration of 0.1 to 100 micromoles/cl is achieved.
Claim 45
Dependent Claim
15 words
The method of claim 41 wherein at least 95 percent of said X are S.
Claim 46
Dependent Claim
39 words
A compound capable of inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host, the compound comprising a mixed linkage oligonucleotide phosphorothioate having a complementary base sequence with a portion of the foreign nucleic acid.
Claim 47
Dependent Claim
39 words
A compound capable of inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host, the compound comprising a mixed linkage oligonucleotide phosphorothioate having a complementary base sequence with a portion of the foreign nucleic acid.
Claim 48
Dependent Claim
38 words
The compound of claim 43 wherein said mixed linkage oligonucleotide phosphorothioate comprises an alternating sequence of nucleoside moieties and linkage moieties such that the linkage moieties are selected from the group consisting of phosphorothioate, methylphosphonate, phosphorotriester, and phosphodiester.
Claim 49
Dependent Claim
47 words
A composition for inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host, the composition comprising a pharmaceutically acceptable carrier and an effective amount of a mixed linkage oligonucleotide phosphorothioate having a complementary base sequence with a portion of the foreign nucleic acid.
Claim 50
Dependent Claim
47 words
A composition for inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host, the composition comprising a pharmaceutically acceptable carrier and an effective amount of a mixed linkage oligonucleotide phosphorothioate having a complementary base sequence with a portion of the foreign nucleic acid.
Claim 51
Dependent Claim
38 words
The composition of claim 45 wherein said mixed linkage oligonucleotide phosphorothioate comprise an alternating sequence of nucleoside moieties and linkage moieties such that the linkage moieties are selected from the group consisting of phosphorothioate, methylphosphonate, phosphorotriester, and phosphodiester.
Claim 52
Independent Claim
47 words
A method for inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host comprising the step of administering to the host an effective amount of a mixed linkage oligonucleotide phosphorothioate having a complementary base sequence with a portion of the foreign nucleic acid.
Claim 53
Independent Claim
47 words
A method for inhibiting the replication or cytopathic effect of a foreign nucleic acid in a host comprising the step of administering to the host an effective amount of a mixed linkage oligonucleotide phosphorothioate having a complementary base sequence with a portion of the foreign nucleic acid.
Claim 54
Dependent Claim
38 words
The method of claim 47 wherein said mixed linkage oligonucleotide phosphorothioate comprises an alternating sequence of nucleoside moieties and linkage moieties such that the linkage moieties are selected from the group consisting of phosphorothioate, methylphosphonate, phosphorotriester, and phosphodiester.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-11-22 | 1997-05-24 | 1997-11-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-11-22 | 2001-05-24 | 2001-11-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-11-22 | 2005-05-24 | 2005-11-23 | $7700.00 | Window Closed / Lapsed |